@article{Kontermann2011,
abstract = {With a growing number of protein therapeutics being developed, many of them exhibiting a short plasma half-life, half-life extension strategies find increasing attention by the biotech and pharmaceutical industry. Extension of the half-life can help to reduce the number of applications and to lower doses, thus are beneficial for therapeutic but also economic reasons. Here, a comprehensive overview of currently developed half-life extension strategies is provided including those aiming at increasing the hydrodynamic volume of a protein drug but also those implementing recycling processes mediated by the neonatal Fc receptor. {\textcopyright} 2011 Elsevier Ltd.},
added-at = {2018-02-01T16:06:35.000+0100},
annote = {Kontermann, Roland EengResearch Support, Non-U.S. Gov'tReviewEnglandCurr Opin Biotechnol. 2011 Dec;22(6):868-76. doi: 10.1016/j.copbio.2011.06.012. Epub 2011 Aug 20.},
author = {Kontermann, Roland E.},
biburl = {https://puma.ub.uni-stuttgart.de/bibtex/2137acc942a2bed5b959cc024609cbf9e/cristiano},
doi = {10.1016/j.copbio.2011.06.012},
edition = {2011/08/25},
interhash = {0e6526909181a7f5888436e5fc213694},
intrahash = {137acc942a2bed5b959cc024609cbf9e},
isbn = {0958-1669},
issn = {09581669},
journal = {Current Opinion in Biotechnology},
keywords = {2011 izi kontermann},
number = 6,
pages = {868--876},
pmid = {21862310},
timestamp = {2018-07-25T12:31:54.000+0200},
title = {{Strategies for extended serum half-life of protein therapeutics}},
url = {https://www.ncbi.nlm.nih.gov/pubmed/21862310},
volume = 22,
year = 2011
}